168 related articles for article (PubMed ID: 18554701)
1. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer.
Onujiogu N; Lengyel E; Yamada SD
Gynecol Oncol; 2008 Dec; 111(3):537-9. PubMed ID: 18554701
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
Landrum LM; Hyde J; Mannel RS; McMeekin DS; Moore KN; Walker JL
Gynecol Oncol; 2011 Sep; 122(3):527-31. PubMed ID: 21664657
[TBL] [Abstract][Full Text] [Related]
3. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
8. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
Dizon DS; Sill MW; Gould N; Rubin SC; Yamada SD; Debernardo RL; Mannel RS; Eisenhauer EL; Duska LR; Fracasso PM
Gynecol Oncol; 2011 Nov; 123(2):182-6. PubMed ID: 21820161
[TBL] [Abstract][Full Text] [Related]
9. Recurrent metastatic fallopian tube carcinoma in pregnancy.
Adolph A; Le T; Khan K; Biem S
Gynecol Oncol; 2001 Apr; 81(1):110-2. PubMed ID: 11277660
[TBL] [Abstract][Full Text] [Related]
10. Reversible posterior leukoencephalopathy syndrome after carboplatin and paclitaxel regimen for lung cancer.
Imai H; Okuno N; Ishihara S; Nakano S; Higuchi S; Arai T; Tokunaga M; Kobayashi H; Arai T; Mori M
Intern Med; 2012; 51(8):911-5. PubMed ID: 22504249
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
Rowan K
J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
[No Abstract] [Full Text] [Related]
12. A relevant historical perspective on the current toxicity of IP chemotherapy: implications for the future.
Markman M
Gynecol Oncol; 2007 Jun; 105(3):561-2. PubMed ID: 17428522
[No Abstract] [Full Text] [Related]
13. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Matulonis UA; Krag KJ; Krasner CN; Atkinson T; Horowitz NS; Lee H; Penson RT
Gynecol Oncol; 2009 Feb; 112(2):394-9. PubMed ID: 19058838
[TBL] [Abstract][Full Text] [Related]
14. Complete remission with intraperitoneal cisplatin followed by prolonged oral etoposide in a stage IIIc primary leiomyosarcoma of the fallopian tube patient.
Kobayashi Y; Tozawa A; Okuma Y; Kiguchi K; Ishizuka B
J Obstet Gynaecol Res; 2010 Aug; 36(4):894-7. PubMed ID: 20666965
[TBL] [Abstract][Full Text] [Related]
15. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs.
Marinella MA; Markert RJ
Intern Med J; 2009 Dec; 39(12):826-34. PubMed ID: 19220526
[TBL] [Abstract][Full Text] [Related]
16. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
Ivy JJ; Geller M; Pierson SM; Jonson AL; Argenta PA
Gynecol Oncol; 2009 Sep; 114(3):420-3. PubMed ID: 19560189
[TBL] [Abstract][Full Text] [Related]
17. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Gu Y; Shu Y; Xu Q
Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
[TBL] [Abstract][Full Text] [Related]
18. Reversible posterior leukoencephalopathy syndrome induced by vinorelbine.
Chen YH; Huang CH
Clin Breast Cancer; 2012 Jun; 12(3):222-5. PubMed ID: 22424944
[TBL] [Abstract][Full Text] [Related]
19. Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer.
Burkett AM; Cohn DE; Copeland LJ
Gynecol Oncol; 2007 Feb; 104(2):491-3. PubMed ID: 17150244
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
McMeekin DS; Walker JL; Hartenbach EM; Bookman MA; Koh WJ;
Gynecol Oncol; 2009 Jan; 112(1):134-41. PubMed ID: 18962846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
